CD19 and diffuse large B-cell lymphoma: BREYANZI (lisocabtagene maraleucel) is another CD19 targeted therapy and approved for the treatment of adults with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, and is manufactured by Juno Therapeutics, Inc. The therapy was approved by the FDA in February 2021.